SCHEMBL20914061

SCHEMBL20914061

Cc1[nH]c2c(-c3ccccc3)c(C(F)(F)F)nn2c(=O)c1-c1nc2c(OCC(=O)O)cccc2o1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CEPT1 Q9Y6K0 1/20 0.37
▸ POLB P06746 4/20 0.36
▸ MEN1 O00255 4/20 0.36
▸ KMT2A Q03164 4/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.34
▸ F2RL3 Q96RI0 3/20 0.33
▸ PPARD Q03181 4/20 0.33
▸ PPARA Q07869 3/20 0.33
▸ ARF6 P62330 2/20 0.33
▸ PPARG P37231 2/20 0.33
▸ FFAR1 O14842 1/20 0.33
▸ PTGDR2 Q9Y5Y4 1/20 0.33
▸ FABP3 P05413 1/20 0.33
▸ FABP4 P15090 1/20 0.33
▸ MAPT P10636 1/20 0.32
▸ MAT2A P31153 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20913917 0.94 CEPT1 (0.36) CEPT1POLBMEN1KMT2AALDH1A1
SCHEMBL20914412 0.91 F2RL3 (0.37) CEPT1POLBMEN1KMT2AALDH1A1
SCHEMBL20914323 0.90 F2RL3 (0.41) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL20914003 0.89 ARF6 (0.34) CEPT1POLBMEN1KMT2AALDH1A1
SCHEMBL20914046 0.89 POLB (0.34) CEPT1POLBMEN1KMT2AALDH1A1
SCHEMBL20819069 0.89 TNKS (0.37) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL20914040 0.88 ALDH1A1 (0.35) CEPT1POLBMEN1KMT2AALDH1A1
SCHEMBL20913960 0.88 F2RL3 (0.41) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL20913908 0.87 F2RL3 (0.38) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL20913904 0.87 POLB (0.34) CEPT1POLBMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 CEPT1 2703/4885POLB 4311/4885MEN1 2785/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 CEPT1 2703/4885POLB 4311/4885MEN1 2785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback